This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pharma Stock Roundup: FDA Approval for NVO, PFE Products & Other Updates
by Kinjel Shah
FDA approves Novo Nordisk's (NVO) obesity treatment, Wegovy and Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine, Prevnar 20.
Merck (MRK) Signs $1.2B Deal With US for COVID-19 Therapeutic
by Zacks Equity Research
Merck (MRK) is set to supply 1.7 million courses of its oral COVID-19 therapy candidate, molnupiravir, worth $1.2 billion to the U.S. government, following a potential approval or authorization.
Pfizer (PFE) Gets FDA Nod for Pneumococcal Vaccine Prevnar 20
by Zacks Equity Research
Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Pfizer (PFE) closed the most recent trading day at $38.85, moving -0.36% from the previous trading session.
Moderna (MRNA) Seeks Approval for COVID-19 Vaccine in Teens
by Zacks Equity Research
Moderna (MRNA) is seeking authorization for conditional use of its COVID-19 vaccine, mRNA-1273, in adolescents in Europe and Canada.
Pfizer (PFE) Down 3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $38.79, marking a +0.75% move from the previous day.
Biotech Stock Roundup: MRNA COVID-19 Vaccine Update, Drug Approvals for ALKS, MYOV & More
by Zacks Equity Research
The biotech sector was in focus last week with pipeline and regulatory updates from Moderna (MRNA) and Alkermes (ALKS), among others.
Moderna (MRNA) Files for Full Approval of COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) seeks full approval for its COVID-19 vaccine, mRNA-1273, in adults with initiation of rolling submission of a BLA. The company also boosts manufacturing capacity for the vaccine.
CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine
by Zacks Equity Research
CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.
Pfizer (PFE) COVID-19 Vaccine Gets Nod for Adolescents in EU
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) vaccine turns out to be 100% effective in preventing COVID-19 in adolescents aged 12-15 years old.
Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine candidate enters phase III. FDA approves J&J's (JNJ) Rybrevant (amivantamab) for a rare lung cancer
Lumber Liquidators, Planet Fitness, Moderna, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Lumber Liquidators, Planet Fitness, Moderna, Pfizer and BioNTech highlighted as Zacks Bull and Bear of the Day
Here's Why Pfizer (PFE) Has Been Rallying This Year So Far
by Zacks Equity Research
Pfizer's (PFE) stock is up 5.8% this year, riding high on the success of its two-shot vaccine for COVID-19.
Moderna's (MRNA) COVID-19 Vaccine 100% Effective in Teens
by Zacks Equity Research
Moderna (MRNA) reports 100% efficacy of its COVID-19 vaccine in teenagers aged 12 to less than 18.
BioMarin (BMRN) Hemophilia Gene Therapy Gets EMA's Speedy Review
by Zacks Equity Research
The EMA grants accelerated assessment to BioMarin's (BMRN) request for review of valoctocogene roxaparvovec for treating severe hemophilia A.
Merck (MRK) Gets CHMP Nod for Keytruda in Esophageal Cancer
by Zacks Equity Research
The CHMP recommends approval of Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy for the first-line treatment of esophageal and gastroesophageal junction carcinoma in Europe.
Pfizer (PFE) Tests COVID-19 Booster & Pneumococcal Vaccine Combo
by Zacks Equity Research
Pfizer's (PFE) study is testing its pneumococcal vaccine candidate along with COVID-19 booster shot on 600 fully vaccinated adults 60 years and older.
AstraZeneca's (AZN) Coronavirus Vaccine Gets EUA in Japan
by Zacks Equity Research
AstraZeneca's (AZN) COVID-19 vaccine Vaxzevria gets an approval for emergency use in Japan for active immunization of individuals aged 18 years and older.
The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck
Pfizer/BioNTech to Supply 1.8B More Doses of Comirnaty in EU
by Zacks Equity Research
Pfizer (PFE)/BioNTech (BNTX) have a total supply order for 2.4 billion doses of its COVID-19 vaccine, Comirnaty in Europe.
Merck's (MRK) Pneumococcal Vaccine Succeeds in Pediatric Trials
by Zacks Equity Research
Merck's (MRK) 15-valent pneumococcal conjugate vaccine candidate, V114, demonstrates comparable immunogenicity and safety compared to a lower valency vaccine in infants and children.
Pharma Stock Roundup: GSK/SNY COVID-19 Vaccine Data, PFE's New EU Supply Deal
by Kinjel Shah
Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine shows strong antibody response in phase II. Lilly's fifth phase III study on tirzepatide meets all key endpoints
Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data
by Zacks Equity Research
Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.
Corcept's (CORT) Lead Drug Korlym Aids Growth Amid Competition
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug, Korlym, is making good progress. Other pipeline candidates are advancing as well. However, sole dependence on Korlym for growth remains an overhang.